Celemics

Celemics Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of Celemics (331920.KQ) as of Nov 1, 2026 is 19.85. In the previous year, Net Debt to Free Cash Flow Ratio was 2.15 — a change of 821.17% (higher).

Net Debt/FCF

19.85

YoY

821.17%

Last updated:

Net Debt to Free Cash Flow Ratio of Celemics is 2024 19.85 . Net Debt to Free Cash Flow Ratio of Celemics was 2023 2.15 . It decreases by 821.17% higher compared to the previous year.

The Celemics Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2017
-1.72 KRW
Jan 1, 2018
-2.01 KRW
Jan 1, 2019
0.21 KRW
Jan 1, 2020
5.23 KRW
Jan 1, 2021
5.24 KRW
Jan 1, 2022
2.56 KRW
Jan 1, 2023
2.15 KRW
Jan 1, 2024
19.85 KRW
The Celemics Net Debt/FCF history
YEARNet Debt/FCFYoY
19.85+821.17%
2.15-15.76%
2.56-51.21%
5.24+0.30%
5.23+2,358.05%
0.21-110.58%
-2.01+16.89%
-1.72—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Celemics Stock analysis

What does Celemics do? Celemics Inc is a South Korean company based in Seoul, operating within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company provides biotechnology services, focusing on the development and sale of target capture kit products. It also offers immune repertoire analysis solutions and next-generation sequencing solutions. Celemics Inc went public through an IPO on August 21, 2020, and currently employs 63 full-time staff. The company's products are sold in both domestic and international markets. Its headquarters are located in Seoul, South Korea, and it maintains a website at www.celemics.com. The firm's primary business activities include the provision of specialized biotechnology services, with an emphasis on innovative tools and solutions for life science research and applications. Celemics Inc has a presence in the Korean market and extends its reach to global customers, supporting various research and diagnostic needs through its technology-driven services. The company's operational focus remains on developing and delivering advanced biotechnology solutions to meet the evolving demands of the life sciences industry. Celemics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celemics stock

Net Debt to Free Cash Flow Ratio of Celemics is 19.85 in 2024.

Net Debt to Free Cash Flow Ratio of Celemics changed from 2.15 to 19.85, representing a 821.17% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio Celemics since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's Celemics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Celemics

All Key Metrics — Celemics